WO2003076610A2 - Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations - Google Patents
Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations Download PDFInfo
- Publication number
- WO2003076610A2 WO2003076610A2 PCT/FR2003/000833 FR0300833W WO03076610A2 WO 2003076610 A2 WO2003076610 A2 WO 2003076610A2 FR 0300833 W FR0300833 W FR 0300833W WO 03076610 A2 WO03076610 A2 WO 03076610A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- psa
- seq
- klk2
- sequence
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
Definitions
- the present invention relates to the field of biology, genetics and medicine. It relates in particular to new nucleotide sequences associated with alternative splicing events of the genes corresponding to the PSA antigen (prostate specific antigen or KLK3) and to kallikrein-2 (KLK2).
- the invention also relates to methods for detecting the presence or for determining the level of expression of these nucleic acids or the corresponding proteins in biological samples, as well as methods of selecting molecules capable of modulating their activity or their expression.
- the invention is particularly suitable for screening, prognostic, classification or monitoring of cancers, in particular of the prostate and in particular in the differentiation between prostate cancer and benign prostatic hyperplasia (BPH), as well as 'to the development of new therapeutic approaches to these diseases.
- BPH benign prostatic hyperplasia
- Kallikreins correspond to a group of proteins whose protease activity allows post-translational modification of protein precursors to biologically active forms. Some members of this family, kallikrein-3, also known under the name of PSA (“prostate-specific antigen”), and more recently, kallikrein-2 are considered to be the best available markers usable in detection, diagnosis and monitoring of prostate cancer.
- PSA is also produced by non-cancerous prostate epithelial cells, it is often difficult to differentiate patients with prostate cancer from those with benign hyperplastic symptom (BPH).
- BPH benign hyperplastic symptom
- PSA exists in free, uncomplexed form and in complexed form, in particular with alpha-antichymotrypsin.
- the alternative splicing constitutes a mechanism of regulation of the expression of the genes making it possible to generate functional diversity from limited genetic information.
- This highly regulated mechanism can undergo alterations during the development of human pathologies.
- the deregulation of the splicing machinery in cancers can allow the expression of isoforms or variants specifically expressed in certain human tumors. These isoforms may have a determining functional role in the development or maintenance of the pathological state.
- the specific expression of such isoforms constitutes an event of choice for a rational and targeted approach to the development of drugs and / or diagnostic methods.
- a gene expression profiling technology has recently been developed to systematically identify genes and, within these genes, the domains likely to be altered by alternative splicing (WO99 / 46403).
- the present invention now describes novel genetic events associated with alternative splicing of the PSA and KLK2 genes in prostate tissue.
- the present invention results in particular from the construction of a directory of splicing alterations associated with prostate tumor tissues, and from the identification of structural alterations in the PSA and KLK2 genes or in the corresponding mRNAs.
- the present invention thus provides new therapeutic and diagnostic approaches for cancers, in particular prostate cancer.
- RNA extracted from samples of prostate tissue originating from tumor and non-tumor areas of patients with prostate carcinomas was carried out by qualitative differential screening thanks to the implementation of the DATAS technique (described in application n ° WO99 / 46403) T FR03 / 00833
- RNAs from tumor and non-tumor prostate tissue has made it possible to isolate various cDNA fragments derived from human kalikrein 2 and kalikrein 3 (PSA) mRNAs. These results then made it possible to identify a certain number of cDNAs revealing events linked to alternative splicing.
- PSA kalikrein 3
- the present invention therefore describes original molecular events which can lead to the specific expression of isoforms or variants of KLK3 (PSA) and KLK2 in prostate tissue and more specifically in cancerous tissue or tissue associated with benign hyperplasia. (BPH).
- PSA KLK3
- BPH benign hyperplasia
- the present invention provides molecular data which justify the use of one or more of these variants as new therapeutic and diagnostic targets which can advantageously be used in the diagnosis and treatment of cancers and in particular prostate cancer.
- a first aspect of the present application therefore relates to variants of human PSA and KLK2, in particular splicing variants.
- the invention relates to the nucleic acids corresponding to these variants or to the specific alterations which they exhibit, as well as the proteins (or polypeptides or protein domains) encoded.
- Another aspect of the present application relates to methods and tools for detecting the presence of these variants or alterations in biological samples (blood, plasma, urine, serum, saliva, biopsies or cell cultures, etc.), or for determining their ( s) respective quantity (s) or proportion (s).
- Such tools include in particular nucleic probes or primers, antibodies or other specific ligands, kits, supports, chips, etc.
- Detection methods can include hybridization, PCR, chromatography, immunology, etc. These methods are particularly suitable for the detection, characterization, monitoring of progression or 03 00833
- Another aspect of the present application relates to tools and methods for the production of compounds active on the variants described, that is to say capable of modulating their expression or their activity.
- tools and methods include in particular nucleic acids, vectors, recombinant cells (or preparations derived from such cells), binding tests, etc.
- the invention also relates to the compounds thus identified or produced, to pharmaceutical compositions containing them, as well as to their therapeutic uses.
- the present invention is thus applicable to the diagnosis and development of therapeutic strategies for cancers, in particular of the prostate.
- a first aspect of the present application therefore relates to variants of KLK-2 and KLK-3 (PSA), or particular genetic alterations affecting these genes (or the corresponding RNAs or proteins).
- PSA KLK-2 and KLK-3
- a more particular object of the invention relates to nucleic acids corresponding to these variants of human PSA and KLK2 or to the specific alterations which they exhibit, as well as the proteins (or polypeptides or protein domains) encoded.
- K-LM corresponds to the total retention of intron 1 of KLK2 (Genbank access number: AF336106) (David et.al (2002)). David et.al state that the expression of K-LM messenger RNA is restricted to the prostatic epithelium and that the K-LM protein can be detected by immunohistochemistry in secretory epithelial cells (despite no data indicating the specificity of the antibody used). No data indicates the presence of K-LM in T FR03 / 00833
- K-LM appears to be detected in two samples of seminal fluids and in a sample of tissues corresponding to benign prostatic hyperplasia.
- the endogenous form of K-LM could not be detected in prostatic lines (with or without androgen stimulation). No results are shown regarding preferential or differential expression of K-LM in tissues or sera from patients with prostate cancer.
- PSA-LM corresponds to the total retention of PSA intron 1 (David et.al (2002)) (Genbank access number: AF335477, AF335478, AJ459784). David et.al specify that the expression of the messenger RNA of PSA-LM is restricted to the prostatic epithelium and that the protein PSA-LM can be detected by immunohistochemistry in the secretory epithelial cells. No data indicates the presence of PSA-LM in human sera, seminal fluids or tissues corresponding to benign prostatic hyperplasia. The endogenous form of PSA-LM could not be detected in prostatic lines (with or without androgenic stimulation). No results are shown for a 03 00833
- PSA-LM preferential or differential expression of PSA-LM in tissues or sera from patients with prostate cancer.
- Tanaka et.al presents qualitative data for the expression of this variant by RT-PCR in malignant and benign prostatic tissues. The expression of the corresponding protein has not been characterized.
- PA 424 could translate into a mature protein of 156 amino acids. The last 16 amino acids would be different from wild PSA. PA 525 could translate into a mature protein of 214 amino acids. The last 28 amino acids would be different from wild PSA. Riegman et.al present no additional expression data differentiating from messenger RNAs or proteins.
- PA 424 and PA 525 described above are very close to PSA-RP1 and PSA-RP2 which were subsequently isolated (Genbank access numbers: AJ310937, AJ310938) (Heuzé et.al (1999); Heuzé-Vourc'h et.al (2001)).
- COS cell lines transfected with PSA-RP1 and PSA-RP2 cDNAs can express and secrete the corresponding proteins
- Heuzé et.al show no results demonstrating the expression of the PSA-RP1 and PSA-RP2 proteins. endogenous in prostate tissue.
- PSA-RP1 messenger RNA Another group (Meng et.al (2002)) characterized the expression of the PSA-RP1 messenger RNA by Northern and in situ hybridization. No difference in expression could be observed between healthy and tumor microdissect tissue.
- An antibody specific to PSA-RP1 made it possible to detect, by immunohistochemistry, the expression of the protein PSA-RP1 in the cytoplasm epithelilal cells from sections of healthy prostate tissue and tumor.
- PSA-RP5 A PSA variant corresponding to a retention of the 5 ′ part of intron 4, PSA-RP5, was submitted to Genbank (access number: AJ512346)
- PSA-RP4 A variant of PSA comprising a deletion in exon 3, PSA-RP4, was submitted to Genbank (access number: AJ459782).
- a first subject of the invention relates to nucleic acids comprising the sequence of the variants of PSA and KLK2 described in the present application, or a specific part thereof.
- nucleic acids specific for the genetic alterations carried by the PSA and KLK2 variants described in the present application.
- Such nucleic acids can in particular be complementary to mutated regions, retained intronic domains or junctions newly created by deletions.
- Another subject of the invention relates to a nucleic acid comprising all or part of a sequence derived from messenger RNAs (or cDNAs) from KLK2-EHT002 to KLK2-EHT011 and from PSA-EHT001 to PSA-EHT027 or from KLK2-EHTb to KLK2-EHTI and from PSA-EHTa to PSA-EHTu or any combination of these variants as well as their uses for the implementation of a method of diagnosis, detection or monitoring of cancers, in particular prostate cancer and most notably the mild form of the latter, BPH.
- messenger RNAs or cDNAs
- Another object of the invention resides in any nucleic acid characterized in that it comprises a sequence chosen from: a) the sequences SEQ ID NOs: 1 to 49, b) a variant of the sequences SEQ ID NOs: 1 to 49 resulting degeneracy of the genetic code, c) the complementary strand of the sequences SEQ ID NOs: 1 to 49, and d) a specific fragment of the sequences a) to c).
- specific fragment or part designates a fragment characteristic of the variants considered, typically a fragment carrying at least one genetic alteration characteristic of the variants considered. Such specific fragments are therefore distinguished from the wild-type sequence by the presence of their own structural characteristic (eg, mutation, new junction, intron retention, deletion of a sequence, stop codon, new sequence resulting from a shift in the reading frame, etc.) resulting from an alteration event highlighted by the applicants in patients.
- This specific structural characteristic is also designated by the expression "target sequence”.
- fragments according to the invention therefore comprise at least one target sequence as defined above.
- Preferred fragments comprise at least 5 consecutive nucleotides of the sequence considered, preferably at least 8, more preferably at least 12.
- Fragments can comprise up to 50, 75 or 100 nucleotides, or even more.
- the nucleic acids can be DNAs, preferably chosen from cDNAs and gDNAs, or RNAs. They can be synthetic or semi-synthetic nucleic acids, PCR fragments, oligonucleotides, double- or single-stranded regions, etc. Nucleic acids T FR03 / 00833
- the nucleic acids can be used to produce a PSA or KLK-2 variant of the invention in vitro, ex vivo, in vivo or in an acellular transcription system. They can also be used for the manufacture of antisense or interfering molecules (RNAi), capable of reducing the expression or the translation of the corresponding mRNAs in a cell. They can also be used for the production of probes, in particular labeled, allowing, by hybridization reactions, to specifically demonstrate the presence of a mutated form of PSA or KLK-2 of the invention in a sample. They can also be used for the production of nucleic primers, useful for the amplification of a PSA or KLK-2 variant (or of a target sequence of such a variant) in a sample, in particular for the purpose of screening. or diagnostic.
- RNAi antisense or interfering molecules
- another object of the invention relates to a nucleic probe characterized in that it allows the detection of a nucleic acid as defined above, typically by selective hybridization from a population of nucleic acids test.
- the probe comprises the sequence of a nucleic acid as defined above or a (specific) part of the sequence of such a nucleic acid.
- the specific part is preferably characteristic of a variant as described above, in particular a part containing an alteration associated with prostate cancer. It typically comprises from 10 to 1000 nucleotides, preferably from 50 to 800, and is generally single-stranded.
- a particular example of a probe is represented by an oligonucleotide specific and complementary to a region of at least one nucleic acid as defined above.
- the oligonucleotide is typically single-stranded, and generally has 10 to 100 bases. Specific examples of oligonucleotides of the invention are provided in Table 1.
- the oligonucleotides and / or nucleic probes according to the invention can be labeled, for example by means of radioactive, enzymatic, fluorescent, luminescent markers, etc.
- Another subject of the invention relates to a nucleic primer, allowing the (selective) amplification of a nucleic acid as defined above or of a (specific) part of such a nucleic acid.
- the amplified part preferably comprises an alteration characteristic of one of the variants described above, in particular an alteration associated with prostate cancer.
- a primer according to the invention is typically single-stranded, and advantageously composed of 3 to 50 bases, preferably from 3 to 40 and even more preferably from 3 to 35 bases.
- a particular primer is complementary to at least one region of the PSA or KLK-2 gene, or of the corresponding RNA.
- a preferred embodiment resides in a primer consisting of a single-stranded nucleic acid comprising from 3 to 50 nucleotides complementary to at least part of one of the sequences SEQ ID NOs: 1 to 49 or to their complementary strand. Examples of such nucleic acid primers are provided in the experimental section.
- the invention also relates to a pair of primers comprising a sense sequence and a reverse sequence, characterized in that the primers of said pair hybridize with a region of a nucleic acid as defined above and allow the amplification. at least a portion of this nucleic acid.
- Another object of the present application relates to any vector comprising a nucleic acid as defined above.
- They can be plasmids, cosmids, episomes, artificial chromosomes, viruses, phages, etc. Mention may be made of various commercial plasmids such as pUC, pcDNA, pBR, etc.
- the viral vectors mention may be made of retroviruses, adenoviruses, AAVs, herpesviruses, etc.
- Another subject of the invention relates to recombinant cells comprising a nucleic acid or a vector as defined above.
- the cells can be prokaryotic or eukaryotic. Among prokaryotic cells, mention may in particular be made of bacteria such as E. coli. Among the eukaryotic cells, mention may be made of yeast cells or cells of mammals, insects or plants. It can be primary cultures or lines. Mention may be made of COS, CHO, 3T3, HeLa cells, etc.
- compositions comprising a nucleic acid as defined above immobilized on a support.
- the invention relates in particular to compositions comprising a plurality of nucleic acids in admixture, in soluble form or immobilized to a support, the composition comprising at least one nucleic acid as defined above.
- Another subject of the invention relates to a (product comprising a) support on which one or more nucleic acids as defined above are immobilized.
- the support can be solid, flat or not, regular or not, such as for example nylon, glass, plastic, metal, fiber, ceramic, silica, polymer, etc., or any other compatible material.
- the nucleic acids are preferably immobilized at one end, under conditions leaving the molecule accessible for a hybridization reaction.
- the nucleic acids can be precisely arranged on the support, and deposited in several copies.
- one or more specific oligonucleotides are used to characterize each alternative splicing event (see FIG. 9). It is possible in particular to use an oligonucleotide specific for an eliminated exon, allowing the quantification of the long form, and / or an oligonucleotide specific for one of the adjacent exons not involved in splicing, making it possible to quantify the long and short forms of RNA, and / or one or more (eg three) oligonucleotides specific for junctions, one of which is specific for the new sequence generated after splicing, making it possible to quantify the form spliced.
- oligonucleotides can be envisaged, in particular the use of one or two oligonucleotides only. More specifically with regard to the junction oligonucleotides, they are ideally centered on the junctions, even if oligonucleotides offset on the junction can also be used.
- oligonucleotides are used which do not have secondary structures which could interfere with their hybridization capacity.
- the oligonucleotides can be modified in 5 ′ by an NH 2 -C6 group promoting their flexibility and making it possible to establish a covalent bond with the polymer constituting the coating of the support.
- Another subject of the invention relates to a (product comprising a) support on which one or more recombinant cells as defined above are immobilized or cultured.
- the support can be solid, flat or not, regular or not, such as for example nylon, glass, plastic, metal, fiber, ceramic, silica, polymer, etc., or any other compatible material.
- the cells are, for example, distributed in wells of a microplate or immobilized in a gel or on a suitable support.
- the invention also relates to the peptides and protein sequences encoded by all or part of the isoforms KLK2-EHT002 to KLK2-EHT011 and PSA-EHT001 to PSA-EHT027, or KLK2-EHTb to KLK2-EHTI and PSA-EHTa to PSA-EHTu in particular. those described among the sequences SEQ ID NO: 50 to 167 as well as their uses for the implementation of a method of diagnosis, detection or monitoring of cancers, in particular prostate cancer and more particularly of the benign form of the latter, BPH.
- a particular subject of the present application relates to a polypeptide comprising all or a specific part of a sequence chosen from SEQ ID NOs: 50 to 167.
- polypeptides are composed or comprise a sequence or part of a sequence created by the alteration of the gene or corresponding messenger.
- the term “part” preferably designates at least 5 contiguous residues, preferably at least 8, more preferably at least 10, even more preferably at least 15.
- the splicing alterations of the PSA or KLK-2 gene lead to the production of mutated proteins, comprising newly created sequences (target sequences). These can be new sequences (eg, offset translation, insertions), new junctions, etc.
- Particular peptides of the invention correspond to or include all or a specific part of the sequences SEQ ID Nos: 53, 56, 59, 62, 65, 67 (residues 146-150), 70, 71, 73, 76, 79, 81 , 93, 95, 98, 106, 108, 110, 112, 117, 119 (residues 66-70 or 74-79), 121 (residues 117-121), 123 (residues 25-29, 51-55 or 105- 111), 126, 131, 133, 134, 135 (residues 64-68) and 155.
- Another subject of the invention relates to a (product comprising a) support on which one or more polypeptides as defined above are immobilized.
- the support can be solid, flat or not, regular or not, such as for example nylon, glass, plastic, metal, fiber, ceramic, silica, polymer, etc., or any other compatible material.
- the polypeptides are preferably immobilized at one end, under conditions leaving the molecule accessible for an interaction reaction with a specific ligand, such as an antibody.
- the polypeptides can be precisely arranged on the support, and deposited in several copies.
- the invention also relates to specific ligands, preferably peptide, in particular antibodies (polyclonal, monoclonal) and their fragments, specific to the peptide regions characteristic of the proteins coded by KLK2-EHT002-011 and PSA-EHT001-027 or by KLK2-EHTb to KLK2-EHTI and PSA-EHTa to PSA-EHTu (encoded by the retained intronic domains or by specifically created junctions) and their uses for the detection, diagnosis or monitoring of cancers and in particular prostate cancer . In particular, this may involve diagnosing the BPH form and differentiating it from prostate carcinoma.
- another object of the invention relates to any antibody capable of binding, preferably selectively, to a polypeptide as defined above.
- the antibody can be polyclonal or monoclonal. It can also be fragments and derivatives of antibodies having substantially the same antigenic specificity, in particular antibody fragments (eg, Fab, Fab'2, CDRs), humanized, polyfunctional, single-stranded antibodies (ScFv) , etc.
- Antibodies can be produced using conventional methods, including immunizing an animal and recovering its serum (polyclonal) or spleen cells (so as to produce hybridomas by fusion with appropriate cell lines).
- polyclonal antibodies from various species are described in the prior art.
- the antigen is combined with an adjuvant (eg, Freund's adjuvant) and administered to an animal, typically by subcutaneous injection. Repeated injections can be given. Blood samples are collected and immunoglobulin or serum are separated.
- Conventional methods of producing monoclonal antibodies include immunizing an animal with an antigen, followed by the recovery of spleen cells which are then fused with immortalized cells, such as myeloma cells. The resulting hybridomas produce monoclonal antibodies and can be selected by limiting dilutions so as to isolate the individual clones.
- the Fab or F (ab ') 2 fragments can be produced by digestion using a protease according to conventional techniques.
- the invention also relates to a method for producing antibodies, comprising injecting a polypeptide as defined above or an immunogenic fragment thereof into a non-human animal and recovering the antibodies or producer cells antibody.
- the preferred antibodies are antibodies specific for the isoforms of PSA and KLK-2 described in the present application, and essentially non-specific for wild forms.
- the invention relates to hybridomas producing the monoclonal antibodies described above and their use for producing said antibodies.
- the antibodies can be coupled to heterologous fragments such as toxins, markers, drugs or any other therapeutic agent, covalently or not, either directly or through coupling agents.
- the markers can be chosen from radio-markers, enzymes, fluorescent agents, magnetic particles, etc.
- the antibodies of the invention can be used as screening agents or to detect or quantify the presence or amount of PSA or KLK-2 isoforms in samples collected from a subject, typically a biological fluid from 'a mammal, for example from a human.
- Another subject of the invention relates to a (product comprising a) support on which one or more antibodies (or fragments or derivatives) as defined above are immobilized.
- the support can be solid, flat or not, regular or not, such as for example nylon, glass, plastic, metal, fiber, ceramic, silica, polymer, etc., or any other compatible material.
- Antibodies are preferably immobilized by one end, under conditions leaving the molecule accessible for an interaction reaction with a specific antigen.
- the antibodies can be precisely arranged on the support, and deposited in several copies.
- the present application also describes new methods for detecting a pathology or a predisposition to a pathology in a subject, comprising determining the presence, in a sample of said subject, of a nucleic acid, or an alteration genetic or a protein or polypeptide as defined above.
- the determination can be carried out by various techniques, such as sequencing, hybridization and / or selective amplification.
- Methods that can be used to determine the presence of proteins are based, for example, on immuno-enzymatic reactions, such as ELISA, RIA, EIA, etc.
- Techniques that can be used to determine the presence of altered genes or RNA are, for example, PCR, RT-PCR, ligation chain reaction (LCR), PCE or TMA ("Transcriptional Mediated Amplification") technique, gel migration, electrophoresis, in particular DGGE (“denaturing gel gradient electrophoresis”), etc.
- the latter preferably uses a primer or a pair of primers as defined above.
- a particular subject of the invention relates to the use of nucleic acids complementary and specific to fragments of the genes or messengers of
- KLK2-EHT002-011 and from PSA-EHT001-027 or from KLK2-EHTb to KLK2-EHTI and from PSA-EHTa to PSA-EHTu eg, retained intronic domains, junctions PT / FR03 / 00833
- cancers in particular prostate cancer, and more particularly of its benign form, BPH.
- This detection may in particular be carried out by means of DNA chips or by the implementation of a PCR from biological fluids such as blood (notably serum or from purified circulating epithelial cells), urine, seminal fluid, etc.
- the invention also resides in the development and use of immunoassays containing one or more antibodies as described above or fragments thereof. These tests make it possible to individually detect and / or measure a variant using a specific antibody, several variants, in parallel, using the appropriate specific antibodies, or one or more relationships between the isoforms as described above or between said isoforms and other forms described for kallikrein-2 and PSA.
- a particular method comprises bringing a sample from a subject into contact with a probe as defined above, and demonstrating hybridization.
- Another particular method comprises bringing a sample from a subject into contact with a primer or a pair of primers as defined above, and demonstrating an amplification product.
- Another particular method comprises bringing a sample from a subject into contact with an antibody as defined above, and demonstrating an antigen-antibody complex.
- the method of the invention comprises the determination, in parallel, of the presence of several genetic variants or alterations as described above in a sample of a patient.
- the invention can be implemented from various biological samples, in particular from biological fluids (eg, blood, plasma, urine, serum, saliva, etc.), biopsies of tissues or cell cultures, for example, and, more generally, from any sample likely to contain nucleic acids or proteins (or polypeptides).
- biological sample can be treated before the implementation of the method, to facilitate or allow the accessibility of the polypeptides or nucleic acids which it contains.
- the sample can also be purified, centrifuged, fixed, etc., possibly frozen or stored before use.
- the invention relates to a method of detecting the presence of an altered form of KLK-2 or KLK-3 in a subject, comprising bringing into contact, in vitro or ex vivo, of a sample of said subject with a specific probe, primer or ligand as defined above and the determination of the formation of a hybrid, of an amplification product or of a complex, respectively, said formation being indicative the presence of an altered form.
- Another object of the invention resides in a kit which can be used for implementing a method as defined above comprising i. a pair of primers or a probe or an antibody as defined above, and ii. the reagents necessary for amplification or for a hybridization or immunological reaction.
- the invention also resides in the development of a method making it possible to detect and / or measure specific partners of one or more of these variants by adding one or more of these variants or their fragments in biological fluids to be tested, such as blood (serum in particular), urine or seminal fluid. Screening of active compounds
- KLK2 and KLK3 according to the invention have been identified and isolated from pathological subjects and therefore represent therapeutic targets which are particularly advantageous for the treatment of cancers and in particular prostate cancer.
- a particular object of the invention resides in methods of selection, identification, characterization, optimization or production of active compounds, comprising a step of determining the capacity of a test compound to modulate the expression or activity of a polypeptide as defined above.
- the compounds are more particularly selected on the basis of their capacity to modulate the synthesis of a polypeptide as defined above (that is to say in particular the production or the maturation of the corresponding RNAs, or their translation) or the activity of such a polypeptide (that is to say in particular their maturation, transport, or their interaction with intra- or extracellular targets).
- the method comprises contacting in vitro or ex vivo a test compound with a polypeptide as defined above or a nucleic acid encoding such a polypeptide (eg, gene, cDNA, RNA), and selecting compounds that bind to said polypeptide or nucleic acid.
- a polypeptide as defined above or a nucleic acid encoding such a polypeptide (eg, gene, cDNA, RNA)
- selecting compounds that bind to said polypeptide or nucleic acid eg, gene, cDNA, RNA
- the binding of the polypeptide to the gene or to the corresponding RNA can be measured by various techniques, such as the displacement of a labeled ligand, migration on gel, electrophoresis, etc. It can be carried out in vitro, for example using the polypeptide or the nucleic acid immobilized on a support.
- the method comprises contacting in vitro or ex vivo a test compound with a cell expressing a polypeptide as defined above, and the selection or identification of compounds modulating the expression or activity of said polypeptide.
- the modulation of expression can be determined by assaying the RNAs or proteins, or by means of a reporter system.
- the cells used can be any compatible cell, in particular eukaryotic or prokaryotic cells as mentioned above.
- a modified cell is typically used to express said molecule, in particular recombinant cells.
- Such recombinant cells can be prepared by the introduction of a recombinant nucleic acid expressing the polypeptide, or of a vector comprising the latter. Such recombinant cells constitute particular objects of the invention.
- the method can be implemented to select or identify an activator or an inhibitor of the expression or of the activity of the specific antigen of PSA or of KLK-2.
- the selection methods can be carried out in different formats, such as for example in multi-well plates, by testing multiple candidate compounds in parallel.
- the compound is an antisense nucleic acid capable of inhibiting the expression of the variants described.
- the antisense nucleic acid can comprise all or part of specific sequences of the variants described.
- the antisense can in particular comprise a region complementary to the identified splicing form (e.g., of a target sequence), and inhibit (or reduce) its translation into protein.
- the compound is a chemical compound, of natural or synthetic origin, in particular an organic or inorganic molecule, of vegetable, bacterial, viral, animal, eukaryotic, synthetic or semi-synthetic origin, capable of modulating the expression or activity of one or more of the variants described above.
- Specific compounds are preferred, that is to say capable of modulating the expression or the activity of the variants, without significantly affecting the expression or the activity of the wild forms.
- the compounds thus identified can be used for the preparation of a composition intended for the treatment of prostate cancer.
- Another object of the invention resides in the use of a compound capable of modulating, ie stimulating, inhibiting or reducing, the expression of one or more variants as described above, for the preparation of a composition intended for the treatment of cancers and in particular prostate cancer.
- treatment designates preventive, curative or palliative treatment, as well as the management of patients (reduction of suffering, improvement of lifespan, slowing down the progression of the disease ), etc.
- the treatment can also be carried out in combination with other active agents.
- Another subject of the invention relates to methods of selection, identification, or characterization of active compounds which can be used in the context of the preparation of compositions intended for the treatment of cancerous pathologies, comprising contacting one or more test compounds with cellular extracts expressing the proteins described in the present invention, or with said purified proteins.
- the invention also relates to a method for producing a medicament for the treatment of cancers, in particular prostate cancer, comprising (i) the selection of active compounds according to the above methods and (ii) the conditioning of said compound or a functional analog thereof in the presence of a pharmaceutically acceptable carrier.
- the functional analog is typically a compound derived from the active compound identified, for 03 00833
- the functional analog may be a "pro-drug" of the identified compound.
- Techniques for preparing functional analogs are well known to those skilled in the art, for example molecular modeling, coupling of NO groups, etc.
- the method may in this regard comprise an intermediate step of synthesis of the selected compound or of the functional analog thereof.
- the pharmaceutically acceptable vehicle or excipient can be chosen from buffer solutions, solvents, binders, stabilizers, emulsifiers, etc.
- Buffer or diluent solutions include dicalcium phosphate, calcium sulfate, lactose, cellulose, kaolin, mannitol, sodium chloride, starch, powdered sugar and hydroxy propyl methyl cellulose (HPMC) (for delayed release).
- Binders are for example starch, gelatin and filling solutes such as sucrose, glucose, dextrose, lactose, etc.
- Natural or synthetic gums can also be used, such as alginate, carboxymethylcellulose, methylcellulose, polyvinyl pyrrolidone, etc.
- excipients are for example cellulose and magnesium stearate.
- Stabilizing agents can be incorporated into the formulations, such as for example polysaccharides (acacia, agar, alginic acid, guar gum and tragacanth, chitin or its derivatives and cellulose ethers.
- Solvents or solutes are for example the Ringer solution, l , distilled water, phosphate buffers, phosphate salt solutions, and other conventional fluids.
- Another subject of the invention relates to the use of cytotoxic ligands specific for one or more variants as described above located on the surface of cancer cells and in particular prostate cancer cells.
- Table 1 Sequence of specific oligonucleotides (SEQ ID NOs: 168-220). Column 1: Name of the oligonucleotide. Column 2: Sequence of the oligonucleotide. Column 3: SEQ ID NO of the oligonucleotides claimed.
- Table 2 Couples of primers used for the amplification of the PSA and KLK2 isoforms.
- Table 3 Values of the fluorescence signals obtained by hybridization from human tissue (Clontech) from a micro-array grouping together oligonucleotides including the oligonucleotides SEQ ID NOs: 168-220.
- Column 1 Name of the oligonucleotide.
- Column 2 SEQ ID NO.
- Column 3-4 Values corresponding to prostate / heart.
- Column 5-6 Values corresponding to prostate / kidney.
- Column 7-8 Values corresponding to prostate / prostate.
- Column 9-10 Values corresponding to prostate / small intestine.
- the sign # N / A indicates that the value was less than twice the background noise.
- Table 4 Values of the fluorescence signals obtained by hybridization from cell lines of a micro-array grouping together oligonucleotides including the oligonucleotides SEQ ID NOs: 168-220.
- Column 1 Name of the oligonucleotide.
- Column 2 SEQ ID NO.
- Column 3-4 Values corresponding to Mda2b / BT549.
- Column 5-6 Values corresponding to Mda2b / MCF7.
- Column 7-8 Values corresponding to Mda2b / Mda231.
- Column 9-10 Values corresponding to Mda2b / T47D.
- the sign # N / A indicates that the value was less than twice the background noise.
- Table 5 Values of the fluorescence signals obtained by hybridization from benign and tumor tissues originating from patients with prostate cancer from a micro-array grouping together oligonucleotides including the oligonucleotides SEQ ID NOs: 168-220.
- Column 1 Name of the oligonucleotide.
- Column 2 SEQ ID NO.
- Column 3-4 Values corresponding to the tumor tissue / benign tissue of the patient 15068.
- Column 5-6 Values corresponding to the tumor tissue / benign tissue of the patient 9648.
- Column 7-8 Values corresponding to the tumor tissue / benign tissue of the patient 8827
- Column 9-10 Values corresponding to the patient's tumor tissue / benign tissue 10063.
- the sign # N / A indicates that the value was less than twice the background noise.
- Figure 1 Arrangement of specific oligonucleotides. Oligonucleotides materialized by rectangles are designed to hybridize specifically to splicing events: intron retention, exon deletion, use of 3 'and 5' cryptic sites.
- Figure 2 Arrangement of specific oligonucleotides. Five oligonucleotides materialized by a line can be designed to analyze the expression of a long form materialized by 3 exons and a short form materialized by 2 exons.
- Figure 3 Marking of long and short synthetic shapes. Synthetic RNAs are produced from linearized plasmids expressing the corresponding cDNAs. The RNAs of the long form are labeled using cyanine 3, the RNAs of the short form are labeled using cyanine 5.
- Figure 4 Demonstration of the specificity of hybridization of oligonucleotides. Five oligonucleotides were used to differentiate the long forms from the short forms mixed in equal amounts. Two examples are presented, gene A and gene B.
- Figure 5 Quantitative measures of relationships between long and short forms. The percentage of long form (wt) has been established at: 0, 20, 40, 60, 80 and 100% (3 examples are presented, gene A, B and C).
- FIG. 6 Specificity of the PSA and KLK2 oligonucleotide micro-array.
- the PSA specific oligonucleotides are revealed by the cyanine labeled PSA isoforms.
- the KLK2 specific oligonucleotides are revealed by the cyanine labeled KLK2 isoforms.
- Figure 7 Diagram of the linear amplification of RNA.
- Figure 8 Example of hybridization of the PSA / KLK2 slide using probes from tumor and healthy tissue from the same patient.
- Figure 9 Measurement of the differential expression of certain isoforms of PSA and KLK2 via the analysis of the corresponding discriminating oligonucleotides between tumor tissues and healthy tissues within the same patients.
- Column 1 nature of the isoform
- column 2 corresponding discriminating oligonucleotide
- column 3 to 6 log2 (tumor expression / normal expression ratio).
- Figure 10 Measurement of the differential expression of certain isoforms of PSA and KLK2 via the analysis of the corresponding discriminating oligonucleotides between the prostate cancer cell line (Mda-2b and LNCap) and the breast cancer cell line (T47D) .
- Column 1 nature of the isoform
- column 2 corresponding discriminating oligonucleotide
- column 3.4 log2 (ratio of prostate line expression to breast line expression). Isoforms relatively overexpressed in the prostate line are indicated in orange. Isoforms relatively overexpressed in the breast line are shown in blue.
- Figure 11 Measurement of the differential expression of certain isoforms of PSA and KLK2 via the analysis of the corresponding discriminating oligonucleotides between different human tissues.
- Column 1 nature of the isoform
- column 2 corresponding discriminating oligonucleotide
- column 3, 4, 5 and 6 log2 (ratio of expression of prostate tissue / tissue of heart, kidney, small intestine and prostate respectively). Isoforms that are relatively overexpressed in prostate tissue are shown in orange. Isoforms relatively overexpressed in other tissues are shown in blue.
- Figure 12 Graphic illustration of the fluorescence signals obtained for certain isoforms with normal tissues.
- FIG. 13 PCR amplifications using specific primer oligonucleotides of three PSA isoforms.
- Figure 14 Annotations of three polyclonal antibodies produced. This figure groups together the information concerning the antibodies SE3962, SE3963, SE4101 produced, the epitopes chosen, the peptides synthesized, the coupling to the KLH used and the isoforms capable of being recognized by these antibodies.
- Figure 15 Titers of the three antibodies by ELISA tests.
- Figure 16 Results of "western blots" with the EHT-SE3962 antibody from sera with low total PSA level in A), with average total PSA levels in B), with high total PSA levels in C). Two bands corresponding to expected molecular weights for KLK2-EHT004 and KLK2-EHT006 are observed. The displacement of the signals with increasing doses of the specific synthetic epitope (from 1 to 50 ⁇ g) not observed with a high dose of non-specific peptide at 250 ⁇ g demonstrates the specificity of this antibody.
- Figure 17 Results of "western blots" with the antibody EHT-SE3963 from prostate tissue. A band corresponding to an expected molecular weight for PSA-EHT021 is observed. Two other higher molecular weight bands are also revealed.
- Poly A + RNAs are prepared according to techniques known to those skilled in the art. It may in particular be a treatment using chaotropic agents such as guanidium thiocyanate followed by extraction of the total RNAs using solvents (phenol, chloroform for example). Such methods are well known to those skilled in the art (see Maniatis et al., Chomczynsli et al., Anal. Biochem. 162 (1987) 156), and can be easily implemented using commercially available kits . From these total RNAs, poly A + RNAs are prepared according to conventional methods known to those skilled in the art and described in commercial kits.
- RNAs serve as a template for reverse transcription reactions using reverse transcriptases.
- reverse transcriptases lacking RNase H activity are used. They make it possible to obtain complementary DNA strands of sizes larger than those obtained using conventional reverse transcriptases. Such preparations of reverse transcriptases without RNase H activity are commercially available.
- RNA sequences not paired with complementary DNA are released from these heteroduplexes under the action of RNase H, this enzyme degrading the paired RNA sequences.
- RNase H this enzyme degrading the paired RNA sequences.
- These unpaired sequences represent the qualitative differences which exist between RNAs which are otherwise homologous to one another. These qualitative differences can be located anywhere on the RNA sequence, either in 5 ′ or 3 ′ as within the sequence and in particular within the coding sequence. Depending on their location, these sequences can be not only modifications of splicing but also the consequences of translocations or deletions.
- RNA sequences representing the qualitative differences are then cloned according to techniques known to those skilled in the art and in particular those described in the patent relating to the DATAS technology.
- sequences are grouped together within cDNA banks which constitute qualitative differential banks.
- One of these banks contains exons and introns specific to the healthy situation; the other banks contain the splicing events characteristic of the pathological conditions.
- the fragments derived from the human genes of KLK2 and KLK3 come from these banks.
- RNA pool was treated with Dnase using the "DNA free” kit from the company Ambion (cat. No. 1906). This RNA is then reverse transcribed using the reverse transcriptase from the “High capacity cDNA Archive” kit from the company Aplied Biosystems (cat. No. 4322171).
- the cDNA thus produced serves as a template for PCR reactions in order to specifically amplify different regions of messenger RNAs derived from human kallikrein-2 and kallikrein-3 according to the following protocol:
- Taq polymerase 0.2 ⁇ L
- oligonucleotides used as PCR primers are as follows
- the amplified products are then cloned in the "Topo" system from the company Invitrogen (cat. No. K4600) according to the protocol provided.
- the ligation products are transformed into competent “Top 10” cells.
- the colonies are identified on agar / LB medium supplemented with ampicillin.
- the cDNAs present in these colonies are amplified individually by PCR amplification using primers Sp6 and T7 according to the following protocol:
- Taq polymerase 0.2 ⁇ L
- the amplification products are then purified by P100 to be sequenced using the “Big Dye Terminator” kit from the company Applied Biosystems according to the protocol provided by this supplier. Sequence reactions are analyzed using an Applied Biosystems 3100 sequencer. Table 2 shows the different cDNAs as well as the pairs of priming oligonucleotides used to obtain them and allowing their amplification in a sample.
- the nucleotide numbering refers to the Genbank accession number M18157 unless otherwise specified.
- the reference protein is KLK2 provided with its signal peptide.
- sequences KLK2-EHT002 to KLK2-EHT011 correspond to sequences comprising an open reading phase with a codon for initiating and terminating translation.
- sequences KLK2-EHTb to KLK2-EHTI correspond to sequences expressed of the “ESTs” type which may include one, two or three reading phases with or without an initiation or termination codon of the translation.
- This isoform exhibits i) a partial retention of a 5 ′ part of intron 2 (nt 1935-2020) and ii) a use of two cryptic splicing sites in the part 3 'of exon 3 (nt 3728) and part 5' of exon4 (nt 3937). These two events correspond to consensual splicing sites.
- This KLK2-EHT002 isoform has a stop codon after exon 2 and thus codes for a truncated protein after residue No. 69 (KLK2-EHT002prota / SEQ ID NO: 50). 54 amino acids can be cleaved to form the sequence KLK2- EHT002protb / SEQ ID NO: 51.
- nucleotides corresponding to Genbank positions (M18157) 1821 and 3581 in SEQ ID NO: 1 correspond to C and A while the Genbank reference indicates T and G respectively. These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase. These two changes do not affect the translated protein sequence.
- KLK2-EHT003 (SEQ ID NO: 2): This isoform exhibits i) a total deletion of exon 2 and ii) retention of a 5 'part of intron 4 (nt 4061-4097). These two events correspond to consensual splicing sites.
- This KLK2-EHT003 isoform codes for a protein comprising 34 additional amino acids beyond threonine residue number 15 (KLK2-EHT003prota / SEQ ID NO: 52). These 34 amino acids can be cleaved to form the sequence KLK2-EHT003protb / SEQ ID NO: 53.
- nucleotides corresponding to Genbank positions (M18157) 3774 and 5486 in SEQ ID NO: 2 correspond to C and T while the Genbank reference indicates T and G respectively. These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase. These two changes do not affect the translated protein sequence.
- KLK2-EHT004 (SEQ ID NO: 3): This isoform has a total deletion of exon 3.
- This isoform KLK2- EHT004 codes for a protein comprising 70 additional amino acids beyond threonine residue number 15 (KLK2-EHT004prota / SEQ ID NO: 54). These 70 amino acids can be cleaved to form the sequence KLK2- EHT003protb / SEQ ID NO: 55. The last 16 amino acids are new and could present one or more epitopes specific for this isoform, KLK2- EHT004protc / SEQ ID NO: 56.
- KLK2-EHT006 (SEQ ID NO: 4):
- This isoform presents a use of two cryptic splicing sites in the 3 'part of exon 3 (nt 3728) and the 5' part of exon4 (nt 3937). This event corresponds to consensual splicing sites.
- KLK2-EHT006 codes for a protein of 149 amino acids (KLK2- EHTOO ⁇ prota / SEQ ID NO: 57). 134 amino acids can be cleaved to form the sequence KLK2-EHT006protb / SEQ ID NO 58. The last 12 amino acids are new and could present one or more epitopes specific for this isoform, KLK2-EHT006protc / SEQ ID NO: 59.
- KLK2-EHT007 (SEQ ID NO: 5):
- KLK2-EHT007 exhibits retention of the 5 'part of intron 4. This isoform KLK2-EHT007 codes for a protein of 224 amino acids (KLK2-
- EHT007prota / SEQ ID NO: 60 209 amino acids can be cleaved to form the sequence KLK2-EHT007protb / SEQ ID NO: 61. The last 14 amino acids are new and could present one or more epitopes specific for this isoform, KLK2-EHT007protc / SEQ ID NO: 62.
- KLK2-EHT009 (SEQ ID NO: 6): KLK2-EHT009 presents i) a deletion of a sequence in exon 3 (nt 3671- 3793) and ii) the use of a cryptic splicing site in the part 5 'of exon 4 (nt 3937) (consensual splicing site).
- This KLK2-EHT009 isoform codes for a protein of 123 amino acids (KLK2-EHT009prota / SEQ ID NO: 63). 108 amino acids can be cleaved to form the sequence KLK2- EHT009protb / SEQ ID NO: 64. The last 5 amino acids are new and could participate in one or more specific epitopes of this isoform, KLK2-EHT009protc / SEQ ID NO: 65.
- KLK2-EHT011 (SEQ ID NO: 7): This isoform presents a use of a cryptic splicing site in the 5 'part of exon4 (nt 4041). This event corresponds to consensual splicing sites.
- This isoform KLK2-EHT011 codes for a protein of 165 amino acids (KLK2-EHT011prota / SEQ ID NO: 66). 150 amino acids can be cleaved to form the sequence KLK2-EHT011 protb / SEQ ID NO: 67. The last amino acid replaces a phenylalanine residue with a tryptophan residue and could participate in an epitope specific for this isoform.
- KLK2-EHTb (SEQ ID NO: 8):
- This isoform has a retention of a 5 ′ part of the intron 1 followed by a deletion between positions 701 and 1058 included.
- This KLK2-EHTb isoform codes for a protein comprising 104 additional amino acids beyond threonine residue number 15 (KLK2-EHTb1, SEQ ID NO: 68). These 104 amino acids can be cleaved to form the sequence KLK2-EHTb2, SEQ ID NO: 69. The last 59 amino acids (KLK2-EHTb3, SEQ ID NO: 70) represent a new sequence compared to an already described isoform, K-LM (David et.al, (2002)).
- nucleotides in position 97, 214, 249 of SEQ ID NO: 8 correspond to G, C, T while the reference genbank indicates C, T, C respectively. These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase.
- the mutations 97, 214 do not affect the translated protein sequence.
- the mutation 249 transforms a serine residue into a phenylalanine residue.
- nucleotides 1192-1199, GAAGAACA of the reference genbank are replaced by the nucleotides 303-306, AAAC in SEQ ID NO: 8. The last fifteen amino acids of KLK2-EHTb1 thus replace an open sequence comprising the 17 amino acids component KLK2-EHTb4, SEQ ID NO: 71.
- This isoform uses a cryptic site in intron 1 which occupies the position
- KLK2-EHTc codes for a protein further comprising 6 amino acids beyond the threonine residue number 15 (KLK2-EHTc1, SEQ ID NO: 72). These 6 amino acids can be cleaved to form the sequence KLK2-EHTc2, SEQ ID NO: 73. It may be noted that the nucleotides 1192-1199, GAAGAACA of the reference genbank are replaced by the nucleotides 71-74, AAAC in SEQ ID NO: 9. This change occurs after a stop codon.
- KLK2-EHTd (SEQ ID NO: 10):
- This isoform has a retention of a 5 ′ part of the intron 1 followed by a deletion between positions 657 and 1209 included.
- This KLK2-EHTd isoform codes for a protein comprising at least 41 additional amino acids beyond threonine residue number 15 (KLK2-EHTd1, SEQ ID NO: 74). These 41 additional amino acids can be cleaved to form the sequence KLK2-EHTd2, SEQ ID NO: 75. The last 11 additional amino acids (KLK2-EHTd3, SEQ ID NO: 76) represent a new sequence compared to an already described isoform, K-LM (David et.al, 2002). ). The sequence predicted by continuing translation into intron 1 produces a protein of 83 amino acids after cleavage: KLK2-EHTd4, SEQ ID NO: 77. KLK2-EHTe (SEQ ID NO: 11):
- KLK2-EHTe has an unknown sequence of 140 nucleotides between an exon 2 truncated in 3 'and exon 3. This isoform KLK2-EHTe codes for a protein further comprising 19 amino acids beyond the glycine residue occupying position number 52 (KLK2-EHTe1, SEQ ID NO: 78). These 19 amino acids represent the sequence KLK2-EHTe2, SEQ ID NO: 79.
- KLK2-EHTf (SEQ ID NO: 12): This isoform uses two cryptic sites, the first in the 3 'part of exon 2 (position 1876), the second in intron 2 (position 3349).
- This KLK2-EHTf isoform codes for a protein further comprising 57 amino acids comprised between the histidine residues at position 49 and asparagine at position 70 (KLK2-EHTf1, SEQ ID NO: 80). These 57 amino acids represent the sequence KLK2-EHTf2, SEQ ID NO: 81.
- the nucleotide at position 269 of SEQ ID NO: 12 corresponds to C, while the reference genbank indicates T.
- the mutation 269 transforms a phenylalanine residue into a leucine residue.
- KLK2-EHTJ (SEQ ID NO: 13):
- KLK2-EHTJ codes for a protein comprising one of the two reading phases corresponding to KLK2-EHTJ1 (SEQ ID NO: 82), or KLK2- EHTJ2 (SEQ ID NO: 83).
- KLK2-EHTk codes for a protein comprising one of the two reading phases corresponding to KLK2- EHTk1 (SEQ ID NO: 84) or KLK2-EHTk2 (SEQ ID NO: 85).
- KLK2-EHTI SEQ ID NO: 15:
- This isoform uses a cryptic site in intron 2 at position 2991.
- This isoform codes for a protein comprising one of the three reading phases corresponding to KLK2-EHTI1 (SEQ ID NO: 86), KLK2-EHTI2 (SEQ ID NO : 87) or KLK2-EHTI3 (SEQ ID NO: 88).
- the nucleotide numbering refers to the Genbank accession number M27274 unless otherwise specified.
- the reference protein is PSA provided with its signal peptide.
- sequences PSA-EHT001 to PSA-EHT027 correspond to sequences comprising an open reading phase with a codon for initiating and terminating translation.
- PSA-EHTa to PSA-EHTu sequences correspond to expressed sequences of the “ESTs” type which may include one, two or three reading phases with or without an initiation or termination codon of the translation.
- PSA-EHT001 SEQ ID NO: 16
- This isoform exhibits retention of a deleted fragment of intron 1 (nt 721-
- PSA-EHT001 isoform codes for a protein of 51 amino acids (PSA-EHT001prota / SEQ ID NO: 89). 36 amino acids can be cleaved to form the PSA-EHT001 protb / SEQ ID NO: 90 sequence.
- the nucleotide corresponding to the Genbank position (M27274) 738 in SEQ ID NO: 16 corresponds to G whereas the Genbank reference indicates T. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations introduced by the polymerase cannot be excluded. This change replaces a tryptophan residue with a glycine residue.
- PSA-EHT003 SEQ ID NO: 17
- This isoform exhibits retention of a deleted fragment of intron 1 (nt 721- 874 then 920-1272).
- This PSA-EHT003 isoform codes for a protein of 89 amino acids (PSA-EHT003prota / SEQ ID NO: 91). 74 amino acids can be cleaved to form the sequence PSA-EHT003protb / SEQ ID NO: 92. The last 20 acids (PSA-EHT003protc / SEQ ID NO: 93) represent new information compared to an isoform already described comprising total retention of intron 1
- PSA-EHT004 (SEQ ID NO: 18):
- This isoform uses a 3 ′ cryptic splicing site located in intron 1 at position 1142 (consensus site).
- This isoform PSA-EHT004 codes for a protein of 47 amino acids (PSA-EHT004prota / SEQ ID NO: 94). 32 amino acids can be cleaved to form the sequence PSA-EHT004protb / SEQ ID NO: 95.
- PSA-EHT005 (SEQ ID NO: 19):
- This isoform exhibits retention of a deleted fragment of intron 1 (nt 721-792 then 1149-1272).
- This PSA-EHT005 isoform codes for a protein of 68 amino acids (PSA-EHT005prota / SEQ ID NO: 96). 53 amino acids can be cleaved to form the sequence PSA-EHT005protb / SEQ ID NO: 97. The last 28 acids (PSA-EHT005protc / SEQ ID NO: 98) represent new information compared to an isoform already described including total retention intron 1
- PSA-EHT007 SEQ ID NO: 20:
- This isoform uses a 5 ′ cryptic splicing site located in exon 1 at position 693 and a 3 ′ cryptic site located in intron 1 at position 1149
- This PSA-EHT007 isoform codes for a protein of 23 amino acids (PSA - EHT007prota / SEQ ID NO: 99).
- PSA-EHT008 (SEQ ID NO: 21):
- This isoform uses a 3 ′ cryptic splicing site located in intron 1 at position 1202 (consensus site)
- This PSA-EHT008 isoform codes for a protein of 27 amino acids (PSA-EHT008prota / SEQ ID NO: 100). 12 amino acids can be cleaved to form the sequence PSA-EHT008protb / SEQ ID NO: 101.
- the nucleotide corresponding to the Genbank position (M27274) 679 in SEQ ID NO: 21 corresponds to T whereas the Genbank reference indicates G. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations introduced by the polymerase cannot be excluded. This change replaces a tryptophan residue with a leucine residue.
- PSA-EHT009 (SEQ ID NO: 22): This isoform exhibits retention of a deleted fragment of intron 2 (nt 2119-2447 then 2988-3226).
- This PSA-EHT009 isoform codes for a protein of 69 amino acids (PSA-EHT009prota / SEQ ID NO: 102). 54 amino acids can be cleaved to form the sequence PSA-EHT009protb / SEQ ID NO: 103.
- M27274 the nucleotide corresponding to the Genbank position
- Genbank reference indicates G. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations introduced by the polymerase cannot be excluded. This change does not change the protein sequence. Other point mutations are identified after the stop codon.
- PSA-EHT012 SEQ ID NO: 23
- This isoform uses a 3 ′ cryptic splicing site located in intron 2 at position 2426 (consensus site)
- This PSA-EHT012 isoform codes for a protein of 83 amino acids (PSA-EHT012prota / SEQ ID NO: 104). 68 amino acids can be cleaved to form the sequence PSA-EHT004protb / SEQ ID NO: 105. The last 14 amino acids (PSA-EHT012protc / SEQ ID NO: 106) represent new information with respect to wild type PSA and are therefore likely to include one or more specific epitopes of this isoform.
- nucleotides corresponding to the Genbank positions (M27274) 1966 and 2459 in SEQ ID NO: 23 correspond to A and A while the Genbank reference indicates G and G respectively. These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase. These two changes do not affect the translated protein sequence.
- PSA-EHT013 SEQ ID NO: 24
- This isoform uses a 3 ′ cryptic splicing site located in intron 1 at position 1945 (consensus site)
- This PSA-EHT013 isoform codes for a protein of 75 amino acids (PSA-EHT013prota / SEQ ID NO: 107). 60 amino acids can be cleaved to form the sequence PSA-EHT013protb / SEQ ID NO: 108. These 60 amino acids represent new information compared to wild type PSA and are therefore capable of including one or more specific epitopes of this isoform.
- PSA-EHT015 SEQ ID NO: 25:
- This isoform uses a 5 ′ cryptic splicing site located in exon 1 at position 703 and a 3 ′ cryptic site located in exon 2 at position 2030
- This PSA-EHT015 isoform codes for a protein of 41 amino acids (PSA - EHT015prota / SEQ ID NO: 109).
- the last 30 amino acids represent new information compared to wild type PSA and are therefore likely to include one or more epitopes specific for this isoform.
- the nucleotide corresponding to the Genbank position (M27274) 2094 in SEQ ID NO: 25 corresponds to C whereas the Genbank reference indicates T. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations cannot be excluded introduced by the polymerase. This change replaces a serine residue with a proline residue.
- PSA-EHT016 (SEQ ID NO: 26): This isoform uses a 3 'cryptic splicing site located in exon 2 at position 2053 (consensus site)
- This PSA-EHT016 isoform codes for a protein of 39 amino acids (PSA -EHT016prota / SEQ ID NO: 111). 24 amino acids can be cleaved to form the sequence PSA-EHT016protb / SEQ ID NO: 112. These 24 amino acids represent new information compared to wild type PSA and are therefore likely to include one or more specific epitopes of this isoform.
- PSA-EHT018 SEQ ID NO: 27
- This isoform exhibits retention of a deleted fragment of intron 2 (nt 2119-2588 then 3114-3226).
- This PSA-EHT018 isoform codes for a protein of 69 amino acids (PSA-EHT018prota / SEQ ID NO: 113). 54 amino acids can be cleaved to form the sequence PSA-EHT018protb / SEQ ID NO: 114.
- the nucleotide corresponding to the Genbank position (M27274) 2545 in SEQ ID NO: 27 corresponds to T whereas the Genbank reference indicates A. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations introduced by the polymerase cannot be excluded. This change does not change the protein sequence.
- PSA-EHT019 SEQ ID NO: 28
- This isoform has a deletion of a fragment located in exon 3 (nucleotide 3828-3933).
- This PSA-EHT019 isoform codes for a protein of 100 amino acids (PSA-EHT019prota / SEQ ID NO: 115). 85 amino acids can be cleaved to form the sequence PSA-EHT019protb / SEQ ID NO: 116. The last 6 amino acids (PSA-EHT019protc / SEQ ID NO: 117) represent new information compared to wild type PSA and are thus likely to include one or more specific epitopes of this isoform.
- nucleotides corresponding to Genbank positions (M27274) 3786 and 3943 in SEQ ID NO: 28 correspond to T and A while the Genbank reference indicate C and C respectively. These differences can be explained by the existence of polymorphisms at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase.
- the first change does not change the protein sequence.
- the second replaces a serine residue with an arginine residue.
- PSA-EHT021 SEQ ID NO: 29
- This isoform uses a 3 'cryptic splicing site located in exon 3 at position 3885 (consensus site) and also has a deletion in the 3' part of exon 3 (nucleotides 3903-4025).
- This PSA-EHT021 isoform therefore codes for a protein of 177 amino acids (PSA-EHT021prota / SEQ ID NO: 118). 162 amino acids can be cleaved to form the PSA-EHT021 protb / SEQ ID NO: 119 sequence.
- the new junctions created around residues 69 and 76 represent new information with respect to wild type PSA and are therefore likely to include one or more epitopes specific for this isoform.
- PSA-EHT022 (SEQ ID NO: 30):
- This isoform has a deletion in the 3 ′ part of exon 3 (nucleotides 3903-4025).
- This PSA-EHT022 isoform therefore codes for a protein of 220 amino acids (PSA-EHT022prota / SEQ ID NO: 120). 205 amino acids can be cleaved to form the sequence PSA-EHT022protb / SEQ ID NO: 121.
- the new junction created around residue 119 represents a new information compared to wild type PSA and is therefore likely to include one or more epitopes specific for this isoform.
- the nucleotide corresponding to the Genbank position (M27274) 1966 in SEQ ID NO: 30 corresponds to A while the Genbank reference indicates G. This difference can be explained by the existence of a polymorphism at this position, by errors in the referenced sequence, although mutations introduced by the polymerase cannot be excluded. This change does not change the protein sequence.
- PSA-EHT022 (SEQ ID NO: 30) corresponds to a PSA variant submitted to Genbank on October 24, 2002 (access number: AJ459782).
- PSA-EHT023 SEQ ID NO: 31
- This isoform comprises a deletion of a fragment of exon 2 (nucleotides
- This isoform codes for a protein of 207 amino acids (PSA-EHT023prota / SEQ ID NO: 122). 192 amino acids can be cleaved to form the PSA-EHT023protb / SEQ ID NO: 123 sequence.
- the new junctions created around residues 27, 53 and in region 105-111 represent new information compared to wild type PSA and are thus likely to include one or more specific epitopes of this isoform.
- nucleotides corresponding to the Genbank positions (M27274) 2060 and 5731 in SEQ ID NO: 31 correspond to G and to G while the Genbank reference indicates T and T respectively. These differences can be explained by the existence of polymorphisms at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase.
- the first change replaces a cysteine residue with a glycine residue.
- the second does not modify the protein sequence.
- PSA-EHT025 (SEQ ID NO: 32): This isoform corresponds to the deletion of exon 3.
- This isoform codes for a protein of 85 amino acids (PSA-EHT025prota / SEQ ID NO: 124). 70 amino acids can be cleaved to form the sequence PSA-EHT025protb / SEQ ID NO: 125. The last 16 amino acids (PSA-EHT025protc / SEQ ID NO: 126) represent new information compared to wild type PSA and are thus likely to include one or more specific epitopes of this isoform.
- nucleotides corresponding to the Genbank positions (M27274) 2118-4186 and 5791 in SEQ ID NO: 32 correspond to G and to G whereas the reference Genbank indicates AT and C respectively. These differences can be explained by the existence of polymorphisms at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase. The agreement of the 3 'sites of exon 2 and 5' of exon 4 suggests a mutation introduced by the polymerase in this region. The last change does not change the protein sequence.
- PSA-EHT026 SEQ ID NO: 33
- This isoform has a deletion of a fragment located in exon 3 (nucleotide 3781-4025).
- This PSA-EHT026 isoform codes for a protein of 78 amino acids (PSA-EHT026prota / SEQ ID NO: 127). 63 amino acids can be cleaved to form the sequence PSA-EHT026protb / SEQ ID NO: 128.
- PSA-EHT027 (SEQ ID NO: 34) This isoform uses a cryptic splicing site located 5 ′ in exon 3 at position 3780 and a deletion of exon 4
- PSA-EHT027 codes for a protein of 144 amino acids (PSA-EHT027prota / SEQ ID NO: 129). 129 amino acids can be cleaved to form the sequence PSA-EHT027protb / SEQ ID NO: 130.
- the last 67 amino acids (PSA-EHT027protc / SEQ ID NO: 131) represent new information compared to wild type PSA and are therefore likely to include one or more epitopes specific for this isoform.
- PSA-EHTa SEQ ID NO: 35
- This isoform has a retention of 91 nucleotides from the 5 ′ part of intron 1 followed by a deletion of the following 152 nucleotides (to then find intron 1).
- This PSA-EHTa isoform codes for a protein of 90 amino acids (PSA-EHTa1, SEQ ID NO: 132) whose last 75 amino acids can be cleaved (PSA-EHTa2, SEQ ID NO: 133), representing different information by compared to PSA and of which the last 44 amino acids (PSA-EHTa3, SEQ ID NO: 134) represent new information compared to total retention of intron 1 already described (David et.al, (2002)).
- Q replaces P in position 26 of the last 74 amino acids.
- nucleotides at position 90 and 234 of SEQ ID NO: 35 correspond to A, C, while the genbank reference indicates C and T.
- nucleotides G and C at position 243 and 293 also differ compared to the genbank reference. However, these two nucleotides do correspond to a published genomic sequence (Genbank access number: NT_011190). These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although it is not possible to exclude mutations introduced by the polymerase. Thus, a glutamine residue replaced the praline residue (mutation 90), and a threonine residue replaced an isoleucine residue (mutation 234).
- PSA-EHTd (SEQ ID NO: 36): This isoform has a deletion of the last 9 nucleotides of exon 2 and the first 243 nucleotides of exon 3. This isoform PSA-EHTd codes for a protein with a deletion of 84 amino acids (PSA-EHTd1, SEQ ID NO: 135). A new domain is created between the cysteine residue 66 and the threonine residue 151.
- PSA-EHTf SEQ ID NO: 37: This isoform exhibits retention of intron 3 deleted from 105 nucleotides (2420-2526).
- This PSA-EHTf isoform codes for a truncated protein after the asparagine residue number 69 which is substituted by lysine residue (PSA-EHT 1, SEQ ID NO: 136).
- PSA-EHT 1, SEQ ID NO: 136 lysine residue
- PSA-EHTh SEQ ID NO: 38
- This isoform results from the use of a cryptic splicing site within intron 4 (in position 5472).
- This PSA-EHTh isoform codes for a protein comprising one of the two reading phases corresponding to PSA-EHTM (SEQ ID NO: 137) or PSA-EHTh2 (SEQ ID NO: 138). It can be noted that the nucleotides at position 79, 199 and 258 of SEQ ID NO: 38 correspond to C, C and G, while the genbank reference indicates T, T and A. These differences can be explained by the existence of 'a polymorphism at these positions, by errors in the referenced sequence, although a mutation introduced by the polymerase cannot be excluded.
- PSA-EHTj SEQ ID NO: 39
- This isoform results from the use of a cryptic splicing site within intron 4 (in position 5257).
- This PSA-EHTj isoform codes for a protein comprising one of the three reading phases corresponding to PSA-EHTj1 (SEQ ID NO: 139), PSA-EHTJ2 (SEQ ID NO: 140) or PSA-EHTJ3 (SEQ ID NO: 141)
- PSA-EHTk (SEQ ID NO: 40): This isoform has a retention of the 3 ′ part of the intron 3, then a retention of a truncated intron 4 (between positions 4337 and 5516). This isoform codes for a protein comprising one of the three reading phases corresponding to PSA-EHTk1 (SEQ ID NO: 142), PSA-EHTk2 (SEQ ID NO: 143), or PSA-EHTk3 (SEQ ID NO: 144) .
- PSA-EHTI SEQ ID NO: 41
- This isoform uses a cryptic site in exon 4 at position 4274 and another cryptic site in intron 4 at position 4538. It can be noted that the nucleotide in position 79 of SEQ ID NO: 41 corresponds to C, whereas the reference genbank indicates T. This difference can be explained by the existence of a polymorphism at this position, by an error in the sequence referenced, although a mutation introduced by the polymerase cannot be excluded.
- PSA-EHTI codes for a protein comprising one of the three reading phases corresponding to PSA-EHTH (SEQ ID NO: 145), PSA-EHTI2 (SEQ ID NO: 146) or PSA-EHTI3 (SEQ ID NO: 147) . In PSA-EHTI3, this mutation replaces an isoleucine residue with a threonine residue.
- PSA-EHTm (SEQ ID NO: 42): This isoform exhibits retention of a truncated intron 1 (between 1214 and 1755).
- PSA-EHTm codes for a protein comprising one of the three reading phases corresponding to PSA-EHTm1 (SEQ ID NO: 148), PSA-EHTm2 (SEQ ID NO: 149) or PSA-EHTm3 (SEQ ID NO: 150) .
- PSA-EHTn SEQ ID NO: 43
- PSA-EHTn codes for a protein comprising one of the three reading phases corresponding to PSA-EHTn1 (SEQ ID NO: 151), PSA-EHTn2 (SEQ ID NO: 152) or PSA-EHTn3 (SEQ ID NO: 153) .
- PSA-EHTp (SEQ ID NO: 44) This isoform results from the use of a cryptic splicing site in intron 1 (in position 1240).
- PSA-EHTp can code for a protein comprising 27 additional amino acids beyond the isoleucine residue occupying position 15 (PSA-EHTp1, SEQ ID NO: 154). These 27 amino acids representing the PSA-EHTp2 sequence (SEQ ID NO: 155) can be released after cleavage.
- PSA-EHTq codes for a protein comprising one of the two reading phases corresponding to PSA-EHTq1 (SEQ ID NO: 156), or PSA-EHTq2 (SEQ ID NO: 157).
- PSA-EHTr SEQ ID NO: 46
- PSA-EHTr codes for a protein comprising one of the three reading phases corresponding to PSA-EHTM (SEQ ID NO: 158), PSA-EHTr2 (SEQ ID NO: 159) or PSA-EHTr3 (SEQ ID NO: 160) .
- PSA-EHTs SEQ ID NO: 47: This isoform exhibits retention of a truncated intron 4 (between positions 4516 and 4889). It can be noted that the nucleotides at positions 54, 93 and 201-208 of SEQ ID NO: 47 correspond to C, A and TGCCGCTG, while the genbank reference indicates T, G and AG-GTGT. These differences can be explained by the existence of a polymorphism at these positions, by errors in the referenced sequence, although a mutation introduced by the polymerase cannot be excluded.
- This isoform codes for a protein comprising one of the two reading phases corresponding to PSA-EHTs1 (SEQ ID NO: 161) or PSA-EHTs2 (SEQ ID NO: 162). The mutation at position 54 replaces in PSA-EHTs1 a leucine residue with a praline residue.
- PSA-EHTt SEQ ID NO: 48
- This isoform has a retention of a truncated intron 4 (between positions 4727 and 5111). It can be noted that the nucleotides at position 137 and 239 of SEQ ID NO: 48 correspond to G and A, while the genbank reference indicates A and G. These differences can be explained by the existence of a polymorphism at these positions , by errors in the referenced sequence, although a mutation introduced by the polymerase cannot be excluded.
- This isoform codes for a protein comprising one of the two reading phases corresponding to PSA-EHTt1 (SEQ ID NO: 163) or PSA-EHTt2 (SEQ ID NO: 164).
- PSA-EHTu SEQ ID NO: 49
- PSA-EHTu codes for a protein comprising one of the three reading phases corresponding to PSA-EHTu1 (SEQ ID NO: 165), PSA-EHTu2 (SEQ ID NO: 166) or PSA-EHTu3 (SEQ ID NO: 167) .
- Mutation 48 replaces the alanine residue with a valine residue in PSA-EHTU2.
- PSA and KLK2 variants described in this invention were established using a micro-array comprising oligonucleotides capable of hybridizing specifically with these variants. Based on their sequences, the PSA and klk2 splicing variants come from events of different natures ( Figure 1). • “exon skipping”: the specific oligonucleotide (eg, discriminant) is drawn to be complementary to the sequence created by the junction exon1-exon3
- the discriminating oligonucleotide is designed to be complementary to (ie, placed on) one or the other of these new junctions.
- oligonucleotides were used to characterize each alternative splicing event (see Figure 2).
- An oligonucleotide is specific for the exon eliminated and allows the quantification of the long form.
- a second oligonucleotide is specific for one of the adjacent exons not involved in splicing and makes it possible to quantify the long and short forms of RNA.
- three oligonucleotides are specific for junctions; among them, one is specific to the new sequence generated after splicing and makes it possible to quantify the spliced shape. It is understood that other combinations of oligonucleotides can be envisaged, in particular the use of one or two oligonucleotides only.
- oligonucleotides Given that the o probes are shorter than the conventionally used PCR product probes, it is necessary to verify that these probes do not hybridize in an aspecific manner other genes than that for which they were designed . In addition, it is essential to ensure that the oligonucleotides do not have secondary structures which could interfere with their hybridization capacity. In general, it is preferable to have a homogeneous thermodynamic profile on the chip for all of the oligos generated, namely the Tm (65 ° C) and the length (24-25 seas). During their synthesis, the oligonucleotides are also modified in 5 ′ by an NH 2 -C6 group promoting their flexibility and making it possible to establish a covalent bond with the polymer constituting the coating of the glass slide.
- junction oligonucleotides are ideally centered on the junctions, but we have also considered the possibilities of oligonucleotides shifted on the junction.
- -% GC 40% to 60% for 24 seas and 30 seas, 30% to 60% for 40 seas.
- FIG. 4 represents the results obtained on two of the clones corresponding to different genes.
- This experiment was carried out with the aim of verifying the specificity of hybridization of our oligonucleotides.
- Drosophila RNA by in vitro transcription in which we have introduced a counterexogen of Arabidopsis thaliana which will be used to calibrate the scanner at the time of reading the slides.
- the labeled isoforms (5 ng per isoforms) are then diluted in the Drosophila cRNA which creates a complex environment allowing us to verify the specificity of the hybridization knowing that the Drosophila RNA does not contain the sequence allowing the hybridization of the target (bioinformatics analysis).
- the slide was read in the 2 channels, that of Cy3 and Cy5. The fluorescence intensity is measured on each spot and the values are normalized by calculating the median.
- Each oligonucleotide is spotted in quadruplet.
- the oligonucleotides corresponding to exon 2, at junctions 1-2 and 2-3 have been drawn to hybridize only the long form, this is why they appear in red on the image generated by QuantArray.
- the specific oligonucleotides of the junction 1-3 are supposed to hybridize only the short forms, they actually appear in green. Since an equimolar mixture of long and short isoforms was used, the superimposition of the two images gives orange spots. (Similar experiments were carried out to determine the sensitivity of our chip by diluting the isoforms up to 26 pg).
- oligonucleotides of 24 and 25 seas have been designed to make the microarray. These oligonucleotides were taken up at a concentration of 25 ⁇ M in a 150 mM sodium phosphate buffer. The oligonucleotides were then deposited on glass slides (Codelink, Amersham), then these slides are incubated in a saturated NaCl chamber for 16 h. The unused reactive sites will then be blocked using a 50 mM ethanolamine solution, 0.1 M Tris, 0.1% SDS at pH 9, they are then washed in a 4xSSC / 0.1% SDS solution.
- the targets are hybridized in the 5X SSC buffer, 0.1% SDS, 0.1 mg / ml salmon sperm DNA, at a temperature of 50 ° C. for 16 h. They are then washed by increasing the stringency of the baths: 4X SSC to eliminate the cover slip 2X SSC / 0.1% SDS for 5 min at 50 ° C 0.2X SSC for 5 minutes at room temperature 0.1X SSC for 5 minutes at room temperature
- the first step is to transfer mRNA in the presence of oligodT using Superscript II.
- RnaseH will degrade the RNA used as a template and leave primers which will be used by DNA polymerase I for the synthesis of the second strand of cDNA.
- the synthesized fragments will be assembled by DNA ligase.
- T7 DNA polymerase it will amplify the strand corresponding to the messenger sequence and synthesize cRNA molecules which will hybridize to probes of complementary sequence (sense of mRNA).
- FIG. 8 represents the superposition of the two images obtained for one of the patients.
- the quality of the fluorescence signal is good, the intensities are generally greater than 1500.
- the slides were read in the 2 channels and the fluorescence intensities were normalized in GeneTraffic according to the global intensity method.
- the slides were read in the 2 channels and the fluorescence intensities were normalized in GeneTraffic according to the global intensity method.
- Tables 3, 4 and 5 group together the hybridization signals obtained on the oligonucleotide microarray from healthy tissues (Table 3), from lines cells (Table 4) and tissues from patients with prostate cancer (Table 5). Values greater than twice the value of background noise representing significant hybridization are shown. Values less than twice the background noise are represented by #NA. It then appears that all the discriminating oligonucleotides except the oligonucleotides SEQ ID NO: 184, 215 and 220 produce significant signals in at least one of the systems studied. The expression of the isoforms described in the present invention is therefore confirmed by this approach. It should also be noted that the PSA-EHT 023 isoform which is associated with the oligonucleotide SEQ ID NO: 184 could be detected by a more sensitive PCR approach (see chapter D below).
- a junction PCR technique was used to reveal the existence of certain isoforms. The principle is based on the specific amplification of the isoforms using oligonucleotides designated specifically on the new junction resulting from the alternative splicing already described. These amplifications are carried out on RNAs originating from benign areas and from tumor areas of prostates of the same patients, as well as on plasmid controls.
- the results of the PCR amplifications are presented in FIG. 13.
- the arrow represents the band of the expected size.
- the plasmid with the cloned isoform serves as a positive amplification control.
- this technique also makes it possible to highlight the presence of certain isoforms in prostate tissue.
- the PCR approach notably revealed the expression of PSA-EHT012.
- Two rabbits were immunized with 200 micrograms of coupled peptide.
- the first injection was made with complete Freunds 'adjuvant, while successive injections were made with incomplete Freunds' adjuvant.
- a standard protocol was used comprising injections on days 0, 14, 28 and 56 and collections of sera on days 0, 38 and 66. The final bleeding took place on day 87.
- the change in titer in the sera was was performed by ELISA test ( Figure 15).
- the antigens, synthetic peptides or KLH were applied to the wells of the ELISA plates (100 nanograms in PBS at 4 ° C for 16 hours).
- the extracts were quantified by the
- the PSA and KLK2 variants are then detected by incubation of the membrane with a polyclonal antibody produced specifically (see previous chapter). After washing, the membrane is incubated with a secondary anti-immunoglobulin antibody labeled with HRP peroxidase (dilution 1/5000). The bands are then visualized by ECL detection (Amersham).
- This antibody was generated against a junction epitope corresponding to PSA-EHT021 (expected size 20 kD).
- Three bands of molecular weights of approximately 22, 25 and 40 kD are observed from prostate tissue (Figure 17).
- the lower molecular weight band could correspond to PSA-EHT021.
- the 25 kD band could correspond to a variant already described and presenting one of the two splicing events associated with PSA-EHT021 (Tanaka et al, 2000).
- CD CO ⁇ r OO LO CO 00 CM C CO o ⁇ r • co M ⁇ f 3; co CM ⁇ : ⁇ :; : CO - ⁇ o C ⁇ C c 2: 5; N tO ZC _ ° ZZZZ.
- T- 00 LO o ⁇ ": N- 00 co: ⁇ ; C Z ⁇ ⁇ Z ⁇ Z Z Z ⁇ O Z CM t- CO ⁇ ; ⁇ -î - ⁇
- T- CM c ⁇ c ⁇ c ⁇ ⁇ ⁇ o
- T- tt 1 * CM CM CM -Sf * - tt ⁇ CM C ⁇ CM ⁇ ⁇ ⁇ - T- tt tt ⁇ Ffc fl ⁇ ⁇ ⁇ ⁇ Ht ⁇ O ⁇
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03743925A EP1483381A2 (fr) | 2002-03-14 | 2003-03-14 | Variants de kallikrein-2 et kallikreine-3 humaines et leurs utilisations |
US10/503,990 US20050112705A1 (en) | 2002-03-14 | 2003-03-14 | Variants of human kallikrein-2 and kallikrein-3 and uses thereof |
CA002478572A CA2478572A1 (fr) | 2002-03-14 | 2003-03-14 | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations |
AU2003242820A AU2003242820A1 (en) | 2002-03-14 | 2003-03-14 | Variants of human kallikrein-2 and kallikrein-3 and uses thereof |
JP2003574817A JP2005519606A (ja) | 2002-03-14 | 2003-03-14 | ヒトカリクレイン−2及びカリクレイン−3のバリアント並びにそれらの使用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/03186 | 2002-03-14 | ||
FR0203186A FR2837215A1 (fr) | 2002-03-14 | 2002-03-14 | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations |
FR0210975A FR2844278A1 (fr) | 2002-09-05 | 2002-09-05 | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations |
FR02/10975 | 2002-09-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003076610A2 true WO2003076610A2 (fr) | 2003-09-18 |
WO2003076610A3 WO2003076610A3 (fr) | 2004-04-08 |
Family
ID=27806679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/000833 WO2003076610A2 (fr) | 2002-03-14 | 2003-03-14 | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050112705A1 (fr) |
EP (1) | EP1483381A2 (fr) |
JP (1) | JP2005519606A (fr) |
AU (1) | AU2003242820A1 (fr) |
CA (1) | CA2478572A1 (fr) |
WO (1) | WO2003076610A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004056989A2 (fr) * | 2002-12-17 | 2004-07-08 | Exonhit Therapeutics | Variants de la kallikreine-2 et de la kallikreine-3 humaines et leurs utilisations |
US7267956B2 (en) | 1999-01-28 | 2007-09-11 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2008003656A2 (fr) * | 2006-07-03 | 2008-01-10 | Exonhit Therapeutics Sa | Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate |
JP2016187340A (ja) * | 2007-05-10 | 2016-11-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Klk3、psca、またはfolh1抗原を含む組成物および方法 |
WO2020144614A1 (fr) * | 2019-01-10 | 2020-07-16 | Janssen Biotech, Inc. | Néo-antigènes de la prostate et leurs utilisations |
EP3523453A4 (fr) * | 2016-10-05 | 2020-08-19 | Institute Of Environmental Science And Research Limited | Séquences d'arn servant à identifier un liquide organique |
WO2021019386A1 (fr) * | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Récepteur antigénique chimérique anti-hk2 (car) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8753630B2 (en) * | 2008-02-12 | 2014-06-17 | The Board Of Trustees Of The Leland Stanford Junior University | Using EGFRvIII to identify and target cancer stem cells |
US20110177059A1 (en) * | 2008-08-05 | 2011-07-21 | University Of Rochester | Psa and klk2 as therapeutic targets and molecules inhibiting psa and klk2 |
DK3147373T3 (da) * | 2010-07-27 | 2019-08-12 | Genomic Health Inc | Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer |
SG10201605210PA (en) | 2012-01-31 | 2016-08-30 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998046795A1 (fr) * | 1997-04-11 | 1998-10-22 | Baylor College Of Medicine | Methode de depistage du cancer prostatique recidivant |
WO1999046403A1 (fr) * | 1998-03-11 | 1999-09-16 | Exonhit Therapeutics S.A. | Criblage differentiel qualitatif |
EP1033401A2 (fr) * | 1999-02-26 | 2000-09-06 | Genset | Marqueurs de séquence exprimées et protéines humaines codées |
WO2001053455A2 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides associes |
-
2003
- 2003-03-14 AU AU2003242820A patent/AU2003242820A1/en not_active Abandoned
- 2003-03-14 EP EP03743925A patent/EP1483381A2/fr not_active Withdrawn
- 2003-03-14 JP JP2003574817A patent/JP2005519606A/ja active Pending
- 2003-03-14 US US10/503,990 patent/US20050112705A1/en not_active Abandoned
- 2003-03-14 WO PCT/FR2003/000833 patent/WO2003076610A2/fr not_active Application Discontinuation
- 2003-03-14 CA CA002478572A patent/CA2478572A1/fr not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998046795A1 (fr) * | 1997-04-11 | 1998-10-22 | Baylor College Of Medicine | Methode de depistage du cancer prostatique recidivant |
WO1999046403A1 (fr) * | 1998-03-11 | 1999-09-16 | Exonhit Therapeutics S.A. | Criblage differentiel qualitatif |
EP1033401A2 (fr) * | 1999-02-26 | 2000-09-06 | Genset | Marqueurs de séquence exprimées et protéines humaines codées |
WO2001053455A2 (fr) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Nouveaux acides nucleiques et polypeptides associes |
Non-Patent Citations (5)
Title |
---|
EXONHIT THERAPEUTICS: "Exonhit Therapeutics and IDEC Pharmaceuticals announce collaborative agreement in target discovery" EXONHIT: NEWS & EVENTS, [Online] 1 juillet 2002 (2002-07-01), XP002222065 Extrait de l'Internet: <URL:http://www.exonhit.com/html/news/2002 -01-07.htm> [extrait le 2002-11-15] * |
LIU XIU FEN ET AL: "Identification of three new alternate human kallikrein 2 transcripts: Evidence of long transcript and alternative splicing." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 264, no. 3, 2 novembre 1999 (1999-11-02), pages 833-839, XP002222066 ISSN: 0006-291X cité dans la demande * |
MINTZ L ET AL: "Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins." AMERICAN JOURNAL OF HUMAN GENETICS, vol. 69, no. 4 Supplement, octobre 2001 (2001-10), page 275, XP001109272 51st Annual Meeting of the American Society of Human Genetics;San Diego, California, USA; October 12-16, 2001 ISSN: 0002-9297 * |
PORKKA KATI P ET AL: "Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library array." JOURNAL OF PATHOLOGY, vol. 193, no. 1, janvier 2001 (2001-01), pages 73-79, XP008010824 ISSN: 0022-3417 * |
TANAKA TSUTOMU ET AL: "A novel form of prostate-specific antigen transcript produced by alternative splicing." CANCER RESEARCH, vol. 60, no. 1, janvier 2000 (2000-01), pages 56-59, XP002222067 ISSN: 0008-5472 cité dans la demande * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7267956B2 (en) | 1999-01-28 | 2007-09-11 | Gen-Probe Incorporated | Nucleic acid sequences for detecting genetic markers for cancer in a biological sample |
WO2004056989A2 (fr) * | 2002-12-17 | 2004-07-08 | Exonhit Therapeutics | Variants de la kallikreine-2 et de la kallikreine-3 humaines et leurs utilisations |
WO2004056989A3 (fr) * | 2002-12-17 | 2005-01-06 | Exonhit Therapeutics | Variants de la kallikreine-2 et de la kallikreine-3 humaines et leurs utilisations |
WO2008003656A2 (fr) * | 2006-07-03 | 2008-01-10 | Exonhit Therapeutics Sa | Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate |
WO2008003656A3 (fr) * | 2006-07-03 | 2008-03-20 | Exonhit Therapeutics Sa | Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate |
JP2016187340A (ja) * | 2007-05-10 | 2016-11-04 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Klk3、psca、またはfolh1抗原を含む組成物および方法 |
EP3523453A4 (fr) * | 2016-10-05 | 2020-08-19 | Institute Of Environmental Science And Research Limited | Séquences d'arn servant à identifier un liquide organique |
WO2020144614A1 (fr) * | 2019-01-10 | 2020-07-16 | Janssen Biotech, Inc. | Néo-antigènes de la prostate et leurs utilisations |
US11793843B2 (en) | 2019-01-10 | 2023-10-24 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
WO2021019386A1 (fr) * | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Récepteur antigénique chimérique anti-hk2 (car) |
Also Published As
Publication number | Publication date |
---|---|
AU2003242820A1 (en) | 2003-09-22 |
WO2003076610A3 (fr) | 2004-04-08 |
JP2005519606A (ja) | 2005-07-07 |
EP1483381A2 (fr) | 2004-12-08 |
CA2478572A1 (fr) | 2003-09-18 |
US20050112705A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6434444B2 (ja) | 腫瘍の診断と治療を目的とした表面会合抗原の同定 | |
JP6174177B2 (ja) | 腫瘍診断と治療のための表面関連抗原の同定 | |
EP1414477B1 (fr) | SEQUENCES REPETEES DU GENE CA125 ET LEURS UTILISATIONS DANS DES INTERVENTIONs DIAGNOSTIQUES | |
US11441190B2 (en) | Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced SMARCA4 gene expression or protein function | |
US20060275304A1 (en) | Novel tumor antigen useful in diagnosis and therapy of prostate and colon cancer | |
CA2848369A1 (fr) | Gene chimere de gene kif5b et de gene ret, et procede de determination de l'efficacite d'un traitement anticancereux ciblant le gene chimere | |
JPH08510391A (ja) | Mts遺伝子における生殖系統の変異およびmts遺伝子における癌の素因の検出方法 | |
WO2003076610A2 (fr) | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations | |
JP2004533206A (ja) | 化学療法のための標的としてのガン関連遺伝子 | |
WO2004056989A2 (fr) | Variants de la kallikreine-2 et de la kallikreine-3 humaines et leurs utilisations | |
EP1511771B1 (fr) | Anticorps monoclonal anti-aurora-a, son procede d obtention, et ses utilisations dans le diagnostic et le traitement des cancers | |
JP2010017194A (ja) | 肺腫瘍に関連したマーカー分子 | |
FR2837215A1 (fr) | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations | |
FR2844278A1 (fr) | Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations | |
US7008772B1 (en) | Compounds for immunodiagnosis of prostate cancer and methods for their use | |
WO2013119678A1 (fr) | Délétion de lkb1/stk11 dans les mélanomes et procédés associés | |
FR2805279A1 (fr) | Sequences retrovirales associees a des affections cutanees | |
TW200914830A (en) | Genes relating to gastric cancer metastasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003743925 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003242820 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2478572 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003574817 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503990 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003743925 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003743925 Country of ref document: EP |